The Use of High-Flow Nasal Oxygen Therapy in the Management of Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Feasibility Study

Basit Öğe Kaydı
dc.authorwosidKaya, Esat Kivanc/IUM-7795-2023
dc.contributor.authorHanci, Pervin
dc.contributor.authorOcal, Serpil
dc.contributor.authorKaya, Esat Kivanc
dc.contributor.authorTopeli, Arzu
dc.date.accessioned2024-06-12T11:11:55Z
dc.date.available2024-06-12T11:11:55Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractOBJECTIVE: This study investigated the efficacy of high-flow nasal oxygen therapy in patients with severe acute exacerbation of chronic obstructive pulmonary disease admitted to the intensive care unit. MATERIAL AND METHODS: Totally, 23 patients were enrolled in the study. High-flow nasal oxygen therapy was administered with a predefined protocol. Vital signs, Visual Analog Scale for dyspnea, and arterial blood gas parameters were recorded at the beginning under low-flow oxygen support therapy and the 1st, 6th, 12th, and 24th hours of high-flow nasal oxygen therapy. High-flow nasal oxygen therapy duration, intensive care unit length of stay, and intensive care unit, in-hospital, and 60-day mortality were recorded as outcomes and compared according to the presence of pneumonia upon admission. RESULTS: In 12 patients (52.2%), pneumonia was present. High-flow nasal oxygen therapy was applied for a median of 57 hours [49.2-104.5]. Overall decreases were detected in heart rate (P=.001), respiratory rate (P<.001), and Visual Analog Scale for dyspnea (P=.001) during the first 24 hours of the therapy. Although there was an increase in PaCO2 (P=.001), pH increased (P<.001) over time too. No change in partial arterial oxygen pressure (P=.63) and partial arterial oxygen pressure/fraction of inspired oxygen ratio (P=.22) was noted. Nineteen patients (77%) were successfully weaned from high-flow nasal oxygen therapy. While the high-flow nasal oxygen therapy failure rate was 23%, the in-hospital and 60-day mortality rates were 8.6%. Outcomes were not different between patients with and without pneumonia. CONCLUSION: High-flow nasal oxygen therapy was efficient in relieving respiratory distress and well-tolerated with no adverse outcome in severe acute exacerbation of chronic obstructive pulmonary disease patients admitted to the intensive care unit.en_US
dc.identifier.doi10.5152/TurkThoracJ.2022.21268
dc.identifier.endpage342en_US
dc.identifier.issn2149-2530
dc.identifier.issue5en_US
dc.identifier.pmid35943069en_US
dc.identifier.scopus2-s2.0-85137378455en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage336en_US
dc.identifier.trdizinid1171338en_US
dc.identifier.urihttps://doi.org/10.5152/TurkThoracJ.2022.21268
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1171338
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22977
dc.identifier.volume23en_US
dc.identifier.wosWOS:000861083300004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Thoracic Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOxygen Inhalation Therapyen_US
dc.subjectChronic Obstructive Pulmonary Diseaseen_US
dc.subjectPneumoniaen_US
dc.subjectCritical Careen_US
dc.subjectIntensive Careen_US
dc.subjectCritically Illen_US
dc.subjectNoninvasive Ventilationen_US
dc.subjectRespiratory-Failureen_US
dc.subjectLung-Diseaseen_US
dc.subjectCannulaen_US
dc.subjectDyspneaen_US
dc.titleThe Use of High-Flow Nasal Oxygen Therapy in the Management of Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Feasibility Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu